You are here: Industry Insights > BeiGene

News List

BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies pharmaceutical-business-review
September 01, 2020
BeiGene has entered into an exclusive licence agreement with Singlomics (Beijing DanXu) Biopharmaceuticals for neutralising Covid-19 antibodies.
Amgen makes $421m additional investment in BeiGene pharmaceutical-technology
July 15, 2020
Amgen has made an additional investment of approximately $421m to the registered direct offering of ordinary shares of Chinese biotechnology firm BeiGene.
BeiGene submits application for the fifth indication for Tislelizumab Injection PharmaSources/Xiaoyaowan
June 30, 2020
On June 29, the official website of CDE showed that the PD-1 antibody of BeiGene submitted a new indication application for Tislelizumab injection and was accepted.
Chi-Med, BeiGene Enter Clinical Collaboration contractpharma
May 27, 2020
Will evaluate combinations of surufatinib and fruquintinib with tislelizumab for multiple solid tumor cancer indications.
BeiGene doses first patient in phase 1b/2 trial of ZW25 in HER2-positive breast cancer and GEA pharmaceutical-business-review
April 06, 2020
Zymeworks announced that its partner, BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating the former's HER2-targeted bispecific antibody ZW25 in combination with chemotherapy.
BeiGene Announces Supply Update for ABRAXANE® in China BeiGene
March 26, 2020
NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company; As the marketing agent for ABRAXANE in China, BeiGene is working with BMS to restore supply in China.
Amgen commences strategic collaboration with BeiGene to expand oncology presence in China worldpharmanews
January 07, 2020
Amgen announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market.
BeiGene obtains certain rights for Leap Therapeutics’ cancer drug pharmaceutical-technology
January 07, 2020
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing firstwordpharma
January 05, 2020
Raymond James & Associates, Inc. was the placement agent for the equity financing.
BeiGene cancer drug misses mark in Phase III study biospectrumasia
December 22, 2019
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

Previous page 1 2 3 4 Next page